CN1449741A - Embolism material - Google Patents
Embolism material Download PDFInfo
- Publication number
- CN1449741A CN1449741A CN 02106199 CN02106199A CN1449741A CN 1449741 A CN1449741 A CN 1449741A CN 02106199 CN02106199 CN 02106199 CN 02106199 A CN02106199 A CN 02106199A CN 1449741 A CN1449741 A CN 1449741A
- Authority
- CN
- China
- Prior art keywords
- suppository
- aneurysm
- molecular weight
- average molecular
- polysaccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention is aimed at providing a kind of easy-to-operate and quality-stable suppository material. Said aim is resolved by providing a suppository material conlaining polysaccharide ester derivative with 10000-500000 dalton weight-average molecular weight and acyl average substituting degree exceeding 2. It is a suppository suitable for arteriovenous aneurysm, it includes suppository material and proper physiological acceptable water-soluble organic acid and its production method of them.
Description
Technical field
The present invention relates to a kind ofly, relate more specifically to comprise embolism materials and its purposes of the ester derivant of polysaccharide the effective embolism materials of arteriovenous aneurysm.
Background technology
Tremulous pulse and vein can be fluttered and because formation arteriovenous aneurysms such as damage, sclerosis of blood vessels, hypertension, bacterial infection, venous valve disease, deformity local, singularly.Among these arteriovenous aneurysms, have those of the bosselated wall of entocranial artery, for example before internal carotid artery, the brain/anterior communicating artery, middle cerebral artery and vertebra at the bottom of tremulous pulse, be called as cerebral aneurysm, bring out subarachnoid hemorrhage when breaking.It is said that about 10% apoplexy is a subarachnoid hemorrhage, and it is reported to suffer from the patient of this disease annual nearly 30000 in Japan.Allegedly 80% among these patients or more meeting death usually after the recurrence cerebral aneurysm is broken.Therefore, finding that than the stage morning cerebral aneurysm and thromboembolism diseased region should be the optimal paths of prevention subarachnoid hemorrhage.
Conventional method as the thromboembolism cerebral aneurysm, the direct surgical operation of general employing, cutting off and ligation of the female tremulous pulse of aneurysm for example, but they are usually replaced by the operation of blood vessel Medicine and Surgery recently, and this operation comes the thromboembolism cerebral aneurysm by implantation platinum coil to cerebral aneurysm intracavity.Yet, adopt this method of platinum coil to have the shortcoming that material is installed, for example the bubble of complicated shape might make aneurysmal complete thromboembolism failure, the coil of installing when pressurized in aneurysm can cause the recirculation of blood, and the thrombosis that forms in aneurysm may move to normal brain position, causes fatal cerebrum block.
As a kind of method that overcomes above conventional method shortcoming, the inventor has proposed the aneurysmal liquid embolic material of a kind of suitable thromboembolism in the open No.107549/94 of Japan Patent etc., it is used for thromboembolism by this way, the cellulose acetate of injecting water-insoluble macromolecule such as water-soluble solubleness organic solvent is to aneurysm cavity, disperse this water-miscible organic solvent to spread all over this chamber, and precipitate there and solidify macromolecular material with the thromboembolism aneurysm.Because above embolism materials also produces significantly effect to the aneurysm in chamber with complicated shape, it has been be evaluated as useful in theory a kind of.Yet, for example Japan Patent discloses the macromolecule that uses in 107549/94, in prepare better quality, stable suppository with satisfied yield, still there is problem to be solved, because macromolecule has the dissolubility and the viscosity of mutability in the water-miscible organic solvent as dimethyl sulfoxine (this paper can be abbreviated as " DMSO ").
Disclosure of the Invention
Consider aforesaid background, the purpose of this invention is to provide a kind of embolism materials that is used to prepare the suppository that is suitable for arteriovenous aneurysm, it has ease for operation and stabilised quality, and it can have higher productive rate; With and uses thereof.
In various macromolecules with different origins, character and chemical constitution, the inventor concentrates on attention as the physiology and goes up on the derivant of polysaccharide of acceptant material, and studies and screen weight average molecular weight and substituent average substitution degree energetically.As a result, they find that the polysaccharide ester derivant of this hope has the daltonian weight average molecular weight of 10000-500000 and surpasses 2 acyl group average substitution degree.This ester derivant is dissolved in blood deficiently, but has higher relatively dissolubility in water-miscible organic solvent, and has manageable precipitation and solidification rate in blood.Based on these, the inventor finds that above easy to operate and stay-in-grade ester derivant promotion is suitable for the preparation of the suppository of arteriovenous aneurysm.
The inventor has solved in the above purpose one by a kind of embolism materials is provided, and this embolism materials comprises and has 10000-500000 dalton weight average molecular weight and the acyl group average substitution degree surpasses 2 polysaccharide ester derivant.
Further, the inventor has solved in the above purpose another by a kind of suppository that is suitable for arteriovenous aneurysm is provided, and this suppository comprises that embolism materials and suitable physiology go up acceptable water-miscible organic solvent.
In addition, the method for the inventor by providing a kind of preparation to be suitable for the suppository of arteriovenous aneurysm further solved in the above purpose, and it is included in the step that the physiology goes up the above embolism materials of dissolving in the acceptable water-miscible organic solvent.
The invention best mode
As above introduce, the present invention relates to comprise and have the embolism materials that 10000-500000 dalton weight average molecular weight and acyl group average substitution degree surpass 2 polysaccharide ester derivant.The term of mentioning in the present invention " polysaccharide " generally means the macromolecule with saccharide repetitive, and these saccharides are for example glucose, galactose, mannose, rhamnose and xylulose.In these polysaccharide, for example starch, amylose, amylopectin, cellulose, amylopectin (pullulans), elsinans and glucosan, they have glucose repeat units and can not induce blood cell, tissue and blood constituent that undesirable side effect takes place basically, can preferably adopt, because in use, embolism materials of the present invention itself relates to intravascular injection and goes into live body, so that contact with tissue with blood cell.
Therefore, the term " polysaccharide ester derivant " mentioned of the present invention hydrogen atom that comprises polysaccharide hydroxyl wherein is with those of acyl substituted.The example of this acyl group comprises alkyl-carbonyl, for example formoxyl, acetyl group, propiono, butyl, isobutyl group, valeryl, isovaleryl, pivaloyl, hexanoyl, decoyl, acryloyl group ,-acryloyl, pyruvoyl, oxalyl, methoxalyl (methooxalyl) and ethoxalyl-; Naphthene base carbonyl is as cyclopropyl carbonyl, cyclobutyl carbonyl, cyclopentylcarbonyl and cyclohexyl-carbonyl; And aryl carbonyl, for example benzoyl, neighbour-toluyl ,-toluyl, right-toluyl and cinnamoyl, can suitably select them according to the polysaccharide type of purposes and use.According to the type of polysaccharide with treat the variation of type of the arteriovenous aneurysm happening part of thromboembolism, preferably select physiologically acceptable polysaccharide as much as possible, because as above introduce, embolism materials of the present invention itself relates to direct intravascular injection and goes into live body, so that contact with tissue with blood cell.Given this, most preferred acyl group is the alkyl carbonyl group, for example acetyl and propionyl; And in these, when being used as polysaccharide, preferably use acetyl group such as cellulosic monosaccharide.
Among the present invention; as above introduce; a kind of easy to operate and stay-in-grade suppository that is suitable for arteriovenous aneurysm is provided; in above ester derivant; preferred selection is such: have 10000-500000 dalton weight average molecular weight; preferably; 30000-300000 dalton; and more preferably have above weight average molecular weight and ratio ((weight average molecular weight)/(number-average molecular weight)) and be lower than those of 2 (preferably in the proportions of 1.1-1.5); and the acyl group average substitution degree surpasses 2 those, preferred 2.5 or higher.So the reason of regulation weight average molecular weight is, have the polysaccharide ester derivant that is lower than above weight average molecular weight lower limit and in water-miscible organic solvent, have the dissolubility and the easy mobility of improvement, but they can promptly and hardy not precipitate and solidify at the arteriovenous aneurysm intracavity, thromboembolism aneurysm fully, and have a weight average molecular weight higher than the above upper limit those promptly precipitate and solidify at the arteriovenous aneurysm intracavity, but the operability that they have reduced dissolubility and the easy mobility in water-miscible organic solvent and have lost them.In these ester derivants, since have be lower than 2 ratio ((weight average molecular weight)/(number-average molecular weight)) those by molecular composition with same polymeric degree and substitution value, they have the advantage of ease for operation when being prepared into water-miscible organic solvent solution, and are easy to control their precipitation and curing in blood.
It is as follows that regulation acyl group average substitution degree surpasses 2 reason: when substitution value was lower than 2, the polysaccharide ester derivant of gained had lower dissolubility, not good operability and relatively poor processability in water-miscible organic solvent; According to the polysaccharide that uses, this ester derivant is soluble in blood, and may cause unwanted results in the thromboembolism arteriovenous aneurysm.Under the situation of the simple polysaccharide ester derivant with glucose repeat units, because the rising of average substitution degree, they have increased their dissolubility in water-miscible organic solvent, but have reduced the viscosity of they solution forms.Especially; have 2.5 or the ester derivant of higher acyl group average substitution degree; although they have higher relatively weight average molecular weight; by being dissolved in for example water-miscible organic solvent of DMSO; can be prepared into solution; have sufficient viscosity and flexibility, they are injected into the arteriovenous aneurysm chamber by adopting the inner catheter promotion in the thromboembolism surgical operation.Normally, the ester derivant with higher weight average molecular weight has higher precipitation and solidification rate in blood, and forms harder solid matter.By the average substitution degree to 2.5 of adjusting acyl group or higher level; even ester derivant have higher weight average molecular weight (since its in water-miscible organic solvent low aqueous solubility and it can not be injected into the arteriovenous aneurysm chamber easily), also can easily be injected into this chamber.Mean molecule quantity, number-average molecular weight and average substitution degree can pass through or measure according to conventional method.For example, weight average molecular weight and number-average molecular weight can equal " polymer magazine " (Polymer Journal) by Kenji Kamide, Vol.11, No.4, pp.285-298 (1979) disclosed method is measured, " carbohydrate chemistry " (Carbohydrate Chemistry) that average substitution degree can be edited by RoyL.Wissler, publishing house of institute (Academic Press) publishes, Vol.3, pp.201-203 (1963) disclosed method is measured.
Above-mentioned polysaccharide ester derivant can pass through prepared in various methods.Adopting cellulose to enter under the situation of polysaccharide as polysaccharide and introducing alkyl-carbonyl; for example; adopt anhydride; acyl halide; ketenes etc. are as the method for acylating agent; for example; " carbohydrate chemistry " that Roy L.Wissler edits, publishing house of institute publishes; Vol.3; pp.193-198 (1963), and Shu Kanbara edits, Kyoritsu Shuppan Publisher publishes " Kobunshi-Jikken-Gaku (" high-molecular weight experimental research) " Experimental Study on Macromolecules) " disclosed method.The ester derivant that is used for hope of the present invention can prepare according to above method, even adopt the polysaccharide except cellulose, or naphthene base carbonyl or acyl group carbonyl is introduced polysaccharide too.Under the situation of the commercialization polysaccharide ester derivant of weight average molecular weight that can obtain having expection and average substitution degree, can intactly use them.Adopt such commercially available prod independently or by those of above method preparation, when they do not have weight average molecular weight in desired extent, they for example accept to have the part of expection weight average molecular weight with collection as differential chromatography and sedimentary conventional method; Perhaps when above two kinds of products had the average substitution degree that is lower than above desired extent, by using the open as described above middle resterification reaction method of introducing, they can be made with the polysaccharide ester derivant of expection average substitution degree.For preparation ratio ((weight average molecular weight)/(number-average molecular weight)) is lower than 2 polysaccharide ester derivant, for example, as Kenji Kamide in " " polymer magazine " (Polymer Journal) ", Vol.11, No.4, disclosed separatory is made usage among the pp.285-298 (1979), can be applied to ratio ((weight average molecular weight)/(number-average molecular weight)) surpass 2 those.Before the use, the ester derivant of gained is according to the conventional method purification that is generally used for the purification medical high polymer, for example extracts, dialyses, dissolves, concentrates, filtration, deposition, decant, fractional distillation and washing/cleaning, their uses capable of being combined if desired.
These polysaccharide ester derivants are favourable as the embolism materials that is suitable for preparing the suppository that is used for arteriovenous aneurysm.The suppository that is suitable for arteriovenous aneurysm of the present invention comprises above-mentioned polysaccharide ester derivant and the suitable acceptable water-miscible organic solvent of physiology, and randomly the contrast agent of angiography is mixed this suppository in the scope that does not influence the object of the invention.The term that the present invention mentions " water-miscible organic solvent " generally means and is using under the temperature of suppository of the present invention (greatly about 37 ℃ temperature; body temperature as common live body) organic solvent of dissolving polysaccharide ester derivant, this solvent dispersion is gone into blood can not influence health basically.Such representative examples of organic is ethanol, propanol, isopropyl alcohol, acetone, N,N-dimethylacetamide, diethyl ether, ethyl methyl ketone, isobutyl methyl ketone, DMSO and their mixture.In these solvents, put into practice and most preferably adopt DMSO among the present invention, because the polysaccharide ester derivant that its excellent dissolution the present invention uses, and live body had higher safety.
The contrast agent that is used for angiography of the present invention is to be suitable for during the surgical operation and watch what is going on visibly those of arteries and veins tumor embolus situation of fluorescent sctinography, naked eyes afterwards, and can not have any conventional use any in the angiography that restrictedly adopt especially.The example of such medicament is iodide, and it comprises 6-Triiodobenzoic acid (amidotrizoic acid), 6-Triiodobenzoic acid sodium (sodium amidotrizoate), iodine peptide acid (iotalamic acid), metrizoic acid, iodamide, Ioxaglic Acid, iopamidol, iohexol and iotrolan; Bismuth compound, for example bismuth oxide; And metal dust, tantalum powder for example, they can randomly use with appropriate combination.
The suppository that is used for arteriovenous aneurysm of the present invention prepares through following steps usually: add an amount of polysaccharide ester derivant to above-mentioned water-miscible organic solvent, and under heating and stirring condition, in solvent, randomly dissolve this derivant with 1% ultimate density (preferred 3 to 10 weight %) at least by weight.If desired, after the filtration, the ester derivant solution of gained is dispensed into proper container, for example ampoule and bottle, then sterilization, closed container then.The suppository that is used for arteriovenous aneurysm of the present invention at room temperature should have suitable viscosity and free mobility, because in use, it injects the arteriovenous aneurysm chamber through the microtubule as inner catheter.When the concentration with above scope is dissolved in above water-miscible organic solvent, this ester derivant with regulation weight average molecular weight and average substitution degree can be prepared at 20 ℃ has the solution that is lower than 1000 centipoises (cps) viscosity, and preferably about 50 to about 500cps.Because these solution have suitable viscosity, free mobility and ease for operation, they are preferred for adopting the thromboembolism surgical operation of inner catheter.
This suppository of explanation is suitable for the purposes of arteriovenous aneurysm of the present invention now, and this suppository can be applied to arteriovenous aneurysm equally as the liquid embolizing agent of routine.Relate to suppository purposes of the present invention, for example, the thromboembolism surgical operation of inner catheter is adopted in mandatory declaration.All surgery operating technologies adopt the built-in cryptoscope that is equipped with the route map function to be applied to patient, and these patients are clear-headed by local anesthesia and maintenance in principle.At first, in arbitrary thigh of patient, place the 6-fr sheath; Next step implants the 6-fr inner catheter to patient artery through sheath; Then, inject the angiography contrast agent to tremulous pulse through inner catheter; At last, fluoroscopy patient's entocranial artery.Based on the fluoroscopy data, determine following content: position, size and the shape of aneurysm influence, and aneurysmal route, position relation and side Zhi Xunhuan degree between aneurysm pedicel and its female aneurysm.Thereafter, microtubular inserts, and passes inner catheter arrives aneurysm cavity until the top of microtubular deep.Under this situation, when microtubular can not insert aneurysm, perhaps change the shape at microtubular top, perhaps be used in combination lead.When aneurysm is the prerolandic artery Rolando tumor of Willis arterial circulation, before the suppository injection, the microtubular that contrast agent is placed in aneurysm cavity injects aneurysm in advance, oppresses carotid artery simultaneously, in order to avoid suppository flows out away from aneurysm, confirm that then contrast agent stays in intracavity.Aneurysm betides under the situation of tremulous pulse at the bottom of the vertebra, and another inner catheter inserts another thigh of patient, and through another inner catheter insert microsphere to female vein (vain) with middle Herba Clinopodii.
Then, inject the fresh preparation of the identical water-miscible organic solvent be used for this suppository, with flushing inner catheter the inside, then under fluoroscopic observation little by little the injected plug agent to inner catheter.Abreast, angiography contrast agent another inner catheter through inserting at another thigh of patient injects, so that fluoroscopy is confirmed the progress of thromboembolism.When being injected into the arteriovenous aneurysm chamber, water-miscible organic solvent in the arteriovenous aneurysm suppository of the present invention is dispensed into blood immediately, the polysaccharide ester derivant forms the grumeleuse shape material according to the arteriovenous aneurysm cavity shape then, precipitate and be cured to the core of arteriovenous aneurysm from the surface gradually, cause forming water insoluble solids material.In this case, grumeleuse shape material begins precipitation and curing once contacting with blood from the surface of arteriovenous aneurysm, and solidified in a few minutes the inside of material, usually within two minutes.After ester derivant solidified, blood circulation restarted, and whether the existence of fluoroscopic observation aneurysm pedicel.When pedicel exists, repeat identical surgery operating technology with complete thromboembolism arteriovenous aneurysm chamber.
Adopting a preferred scheme of arteriovenous aneurysm suppository of the present invention is the thromboembolism surgical operation, suppository combination or is unceasingly adopted in this operation, for example, with the coil that is used for the thromboembolism arteriovenous aneurysm, the coil of making by titanium, platinum, gold or their alloy or synthetic resin for example.With regard to this method, coil plays arteriovenous aneurysm intracavity " support ", and the polysaccharide ester derivant in coil or around coil precipitation and curing, formation is by they independent any hard solid matters that can not obtain.Thereby, according to this method, even when being applied to have the arteriovenous aneurysm in chamber of larger volume or complicated shape, operation only once can be fully and this arteriovenous aneurysm of semipermanent ground thromboembolism, can not follow any pedicel by remnants, this increases and has enlarged operating effectiveness of arteriovenous aneurysm thromboembolism and range of application significantly by vascular surgery.Suppository of the present invention is used in combination with the coil that is used for the thromboembolism arteriovenous aneurysm, makes coil thromboembolism arteriovenous aneurysm chamber to a certain extent, prevents suppository exhaust chamber when it is injected into the chamber basically.Therefore, according to arteriovenous aneurysm to be treated influence position, size, shape or appearance, the molecular weight and/or the concentration of mixing the ester derivant of suppository are arranged to level slightly lower in the aforementioned range, with the equal even arteriovenous aneurysm of thromboembolism fully chambeies.
Can be with suitable arteriovenous aneurysm according to arteriovenous aneurysm suppository treatment of the present invention, comprise the aneurysm and the varices that generally occur in live body, for example be generally the brain of scrotiform or fusiformis-, in the body cavity-, liver-, splenic artery-, renal artery and periphery-aneurysm, it is for example induced to arteriosclerosis, infected by microbes, inflammation and inhorn characteristic intracranial ground, internal organs ground or periphery by some factors; With the varicosis that usually occurs in esophageal venous plexus, rectal venous plexus, paraumbilical veins, lower limb, pudendum, spermatic cord etc., it is brought out by rising, the minimizing of wall of vein endurance, venosclerosis and the venous valve disease of venous pressure.Equally, this suppository thromboembolism intracranial arteriovenous malformation very effectively.Except above medical application, suppository of the present invention has extensive use, and as those of the relative minor impact part of needs thromboembolism, for example, the hemorrhage of medical domain is used for the hemorrhage of block blood flow in the blood vessel in tremulous pulse and vein in the needs of medical treatment; And the reinforcing agent and the filler that are suitable for cloth, paper, thin film, film and thin slice in cloth, papermaking and the chemical field.
Hereinafter, introduce the preferred embodiments of the invention with reference to the following example:
Embodiment 1: embolism materials
The cellulose acetate of 25 grams; have the acyl group average substitution degree of 50000 daltonian weight average molecular weight and 1.75, insert in the reactor, 110 ℃ of dryings two hours; and mix, at room temperature stir the mixture of gained then and cross liquid with the acetic acid of 500ml and acetic anhydride (by volume=9: 1) solution.Thereafter, the acetum of 11ml and perchloric acid (by volume=10: 1) mixture adding reactor, mixture high-speed stirred 30 minutes then allows reactant mixture precipitate in a conventional manner.The collecting precipitation thing, then according to as Kenji Kamide in " " polymer magazine " ", Vol.11, No.4, successive soln fractionating process (SSF) fractional distillation of report among the pp.285-298 (1979), the identical part of then collecting weight average molecular weight and material.Afterwards, concentrate, precipitate, filter, wash and pulverize this part, obtain 10g powdery cellulose ester derivant, have 50000 daltonian weight average molecular weight, weight average molecular weight is 1.3 with the number-average molecular weight ratio, and the acyl group average substitution degree is 2.9.
Adopt the powder of a part of gained, measure dissolubility, show that it at 20 ℃ of dissolubility that have above 10mg/ml, is insoluble to normal saline basically in DMSO in common mode.In contrast; have 50000 dalton's weight average molecular weight, weight average molecular weight and number-average molecular weight ratio and be the cellulose esters derivant of 2.3 and 1.75 acyl group average substitution degree; equally as above test; show that it is insoluble to normal saline basically, but significantly be lower than the above-mentioned ester derivant of present embodiment at 20 ℃ of dissolubility in DMSO.Sampling of the not fractionated ester derivant of a part in the above preparation process and equally as above test show that it has the dissolubility that significantly is lower than the fractional distillation sample in DMSO, and have quite unwelcome operability during dissolving.
Ester derivant in the present embodiment has higher dissolubility and satisfied operability and quality stability in the water-miscible organic solvent of for example DMSO, be a significant benefit to the embolism materials that acts on thromboembolism arteriovenous aneurysm etc.
Embodiment 2: embolism materials
The amylopectin (pullulan) of 5 grams, have 85000 daltonian weight average molecular weight, weight average molecular weight is 1.5 with the number-average molecular weight ratio, it is by applicant among Japan Patent open No.141401/82s the disclosed method preparation same with the present invention, place reactor and mix with the acetic anhydride of 13g and the pyridine of 30g, mixture was 100 ℃ of reactions two hours.Afterwards, with conventional method precipitation, filtration, washing and pulverizing reactant mixture, obtain the Powdered amylopectin ester derivant of 4 grams, have the weight average molecular weight identical with raw material, weight average molecular weight is 2.7 with the ratio of number-average molecular weight.
Adopt a part of powder obtain thus, measure dissolubility in a usual manner, show it at 20 ℃ of dissolubility in DMSO greater than 10mg/ml, and be insoluble to normal saline basically.In contrast; have 85000 dalton's weight average molecular weight, weight average molecular weight and number-average molecular weight ratio and be the amylopectin ester derivant of 2.1 and 0.95 acyl group average substitution degree; as above test equally; show different with the product of present embodiment, it fully be dissolved in normal saline and 20 ℃ in DMSO dissolubility significantly low.
The ester derivant that present embodiment obtains has higher dissolubility and satisfied operability and quality stability in the water-miscible organic solvent of for example DMSO, be a significant benefit to the embolism materials that acts on thromboembolism arteriovenous aneurysm etc.
Embodiment 3: suppository
The DMSO of quantity sufficient puts into glass container, mixes with the ester derivant of the method preparation of the embodiment 1 of 12.5g or 2, and stirring is thoroughly dissolved until this ester derivant during heating, and adding DMSO then is 150ml up to cumulative volume.Afterwards, adopt glass syringe and the aspirating needle be furnished with filter membrane, the gained solution that distributes 3 ml aliquots samples during heating is to the brown ampoule of 5-ml, and 115 ℃ of autoclavings 30 minutes, the sealing by fusing ampoule obtained two types suppository then.
An ampoule of every kind of suppository that present embodiment obtains is unsealed, and the inclusions inhalation syringe in each ampoule, and dropwise dropwise add the normal saline of 37 ℃ of insulations is observed them separately with spherical mode moment precipitation with solidify.For relatively, adopt following contrast, observe them and splash into the dynamic of normal saline; 1 cellulose esters derivant has 50000 daltonian weight average molecular weight in contrast, 2.3 weight average molecular weight and number-average molecular weight ratio, and 1.75 acyl group average substitution degree; With another kind of cellulose esters derivant; in contrast 2; have 5000 daltonian weight average molecular weight; 1.3 weight average molecular weight and number-average molecular weight ratio; and 2.9 acyl group average substitution degree; they all similarly prepare with the ester derivant of present embodiment, except suitable reduction has the ester derivant precursor concentration of low DMSO dissolubility.As a result, contrast 1 similarly precipitates with suppository of the present invention and solidifies, yet because its lower DMSO dissolubility, it has relatively poor operability in the preparation suppository.Have the dissolubility that is similar to suppository of the present invention and contrast 2, but in normal saline, have significantly lower precipitation and solidification rate.As for the not fractionated ester derivant of preparation among the embodiment 1, observe it and splash into the dynamic of normal saline to above similar, show that it terminates to solidifying from precipitating beginning, has than the remarkable longer time cycle of fractionated ester derivant.
The product that present embodiment obtains has the ability of satisfied thromboembolism arteriovenous aneurysm, viscosity and free mobility fully, and ease for operation, when its when the coil of thromboembolism arteriovenous aneurysm uses alone or in combination, be a significant benefit to suppository as the thromboembolism arteriovenous aneurysm.If desired, fully the suitable angiography contrast agent that is used for the thromboembolism symptom of amount can add this product.
Embodiment 4: clinical case
Adopt computerized tomography (CT) and cerebral angiography, 35 years old patients' male head, it headache break out and confusion after send into hospital, scan and be diagnosed as the subarachnoid hemorrhage that aneurysm rupture causes, aneurysm size 12mm * 12mm is positioned at vertebra tremulous pulse end.At first plan direct surgical operation therapy, yet, because having, discovery do not penetrate blood vessel, carry out the thromboembolism operation that twice employing is suitable for the platinum coil of thromboembolism arteriovenous aneurysm, replace directly operation, and cause the complete basically thromboembolism of aneurysm.
Yet after half a year, this patient's entocranial artery radioscopy is presented at and forms little gap in the aneurysm cavity, and blood flow is recirculation.Therefore, adopt the suppository of the cellulose esters derivant that contains the preparation of embodiment 2 methods, accept the operation of another time thromboembolism, cause the complete thromboembolism success of little gap and aneurysm pedicel according to above-mentioned method patient.After two other month, this patient's entocranial artery radioscopy shows thromboembolism aneurysm no change.Do not observe the serious neurological in operation back and change and the dyskinesia in patient, he can rework.
These results show that polysaccharide ester derivant of the present invention is specially adapted to the thromboembolism arteriovenous aneurysm, the combination of the conventional coil by adopting suppository of the present invention and thromboembolism arteriovenous aneurysm, more effectively thromboembolism arteriovenous aneurysm.Now, the device of the most conventional use of thromboembolism arteriovenous aneurysm is the coil that is used for the employing metal of thromboembolism arteriovenous aneurysm in blood vessel Medicine and Surgery operation, for example platinum coil.Yet, in the use of adopting such coil,,, in aneurysm cavity, can form little gap as the arteriovenous aneurysm alteration of form of coil treatment or the result of coil contraction itself as above case illustration ground, but and blood flow recirculation.When such coil and suppository of the present invention continuously or when being used in combination, coil serves as " support ", polysaccharide ester derivant precipitation and be solidificated within the coil or on every side.Therefore, form hard, solid matter according to the shape of arteriovenous aneurysm, this wherein anyly all can not obtain separately by them.As a result, form the operation interior little gap of arteriovenous aneurysm afterwards hardly.The disruptive risk of blood flow recirculation and arteriovenous aneurysm is minimized.
Industrial applicibility
As mentioned above, the present invention is based on and have the many of regulation weight average molecular weight and regulation average substitution degree Glycolipid derivant draws as self discovery of easy to operate and stay-in-grade embolism materials. Contain ester The suppository of the embolism arteriovenous aneurysm of derivative is by independent use or combination embolism arteriovenous aneurysm Coil, and be applied to accept direct operating arteriovenous aneurysm happening part, directly hand The patient of art failure, performing the operation in view of their size, locations/regions, neurosis etc. has The patient of high phoenix danger, and the patient who is impatient at general anesthesia are for generally following under the arachnoid Treatment and the prevention of hemorrhage, the blood pressure drops of hemorrhage and arteriovenous aneurysm, thrombus and inflammation have obviously Effect. In addition, suppository of the present invention has extensive use, because the relative minor impact of needs section Divide those of embolism, for example, the styptic of medical domain, in the needs of medical treatment in artery and vein The styptic that is used for block blood flow in the blood vessel; And be suitable in cloth, papermaking and the chemical field cloth, paper, The reinforcing agent of film, film and thin slice and filler.
The present invention with these outstanding function and efficacies has significantly having of very big contribution to this area With invention.
Claims (15)
1. embolism materials comprises the polysaccharide ester derivant that has 10000-500000 dalton weight average molecular weight, surpasses 2 acyl group average substitution degree.
2. the embolism materials of claim 1, it is insoluble to blood basically, and the dissolubility at dimethyl sulfoxine under 20 ℃ is 10mg/ml at least.
3. claim 1 or 2 embolism materials, the weight average molecular weight that it has and the ratio of number-average molecular weight are lower than 2.
4. claim 1,2 or 3 embolism materials, wherein said acyl group is an acetyl group.
5. claim 1,2,3 or 4 embolism materials, wherein said polysaccharide is a cellulose.
6. suppository that is suitable for arteriovenous aneurysm, it comprise claim 1 to 5 any one embolism materials and the suitable acceptable water-soluble organic acid of physiology.
7. the suppository of claim 6, wherein said water-miscible organic solvent is a dimethyl sulfoxine.
8. claim 6 or 7 suppository, wherein the ester derivant of polysaccharide has the concentration of at least 1 weight % in described water-miscible organic solvent.
9. claim 6,7 or 8 suppository, it further contains the suitable contrast agent that is used for angiography.
10. claim 6,7,8 or 9 suppository, it has the viscosity that is lower than 1000 centipoises (cps) at 20 ℃.
11. claim 6,7,8,9 or 10 suppository, it is used for cerebral aneurysm.
12. claim 6,7,8,9,10 or 11 suppository, it and the suitable arteriocerebral coil combination that is used for are used.
13. a method of producing suppository, it is included in suitable physiology and goes up in the acceptable water-miscible organic solvent embolism materials of any one in the dissolving claim 1 to 5.
14. the method for claim 13, wherein said water-miscible organic solvent is a dimethyl sulfoxine.
15. the method for claim 13 or 14, wherein the polysaccharide ester derivant in described water-miscible organic solvent has the concentration of at least 1 weight %.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02106199 CN1270780C (en) | 2002-04-09 | 2002-04-09 | Embolism material |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02106199 CN1270780C (en) | 2002-04-09 | 2002-04-09 | Embolism material |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1449741A true CN1449741A (en) | 2003-10-22 |
| CN1270780C CN1270780C (en) | 2006-08-23 |
Family
ID=28680181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02106199 Expired - Fee Related CN1270780C (en) | 2002-04-09 | 2002-04-09 | Embolism material |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1270780C (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1299695C (en) * | 2004-11-16 | 2007-02-14 | 南京大学 | Liquid embolism agent for intracranial aneurysm and its preparing process |
| CN102100933A (en) * | 2010-08-10 | 2011-06-22 | 微创医疗器械(上海)有限公司 | Embolic material composition and preparation method thereof |
| CN102499732A (en) * | 2011-10-19 | 2012-06-20 | 微创医疗器械(上海)有限公司 | Intravascular implanted device bag and preparation method for implanted device |
| WO2012171478A1 (en) | 2011-06-17 | 2012-12-20 | 微创医疗器械(上海)有限公司 | Liquid embolic materials based on collagens and preparation method thereof |
| US10568839B2 (en) | 2011-01-11 | 2020-02-25 | Capsugel Belgium Nv | Hard capsules |
| US11319566B2 (en) | 2017-04-14 | 2022-05-03 | Capsugel Belgium Nv | Process for making pullulan |
| US11576870B2 (en) | 2017-04-14 | 2023-02-14 | Capsugel Belgium Nv | Pullulan capsules |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102764456B (en) * | 2012-07-24 | 2014-10-15 | 上海交通大学 | Vascular occlusive agent, application thereof and preparation method |
-
2002
- 2002-04-09 CN CN 02106199 patent/CN1270780C/en not_active Expired - Fee Related
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1299695C (en) * | 2004-11-16 | 2007-02-14 | 南京大学 | Liquid embolism agent for intracranial aneurysm and its preparing process |
| CN102100933A (en) * | 2010-08-10 | 2011-06-22 | 微创医疗器械(上海)有限公司 | Embolic material composition and preparation method thereof |
| CN102100933B (en) * | 2010-08-10 | 2014-05-07 | 上海微创医疗器械（集团）有限公司 | Embolic material composition and preparation method thereof |
| US10568839B2 (en) | 2011-01-11 | 2020-02-25 | Capsugel Belgium Nv | Hard capsules |
| WO2012171478A1 (en) | 2011-06-17 | 2012-12-20 | 微创医疗器械(上海)有限公司 | Liquid embolic materials based on collagens and preparation method thereof |
| CN102499732A (en) * | 2011-10-19 | 2012-06-20 | 微创医疗器械(上海)有限公司 | Intravascular implanted device bag and preparation method for implanted device |
| US11319566B2 (en) | 2017-04-14 | 2022-05-03 | Capsugel Belgium Nv | Process for making pullulan |
| US11576870B2 (en) | 2017-04-14 | 2023-02-14 | Capsugel Belgium Nv | Pullulan capsules |
| US11878079B2 (en) | 2017-04-14 | 2024-01-23 | Capsugel Belgium Nv | Pullulan capsules |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1270780C (en) | 2006-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69929588T2 (en) | Gynecological embolization and kit for it | |
| US20040241094A1 (en) | Oily paclitaxel composition and formulation for chemoembolization and preparation method thereof | |
| JP2002519364A (en) | Vascular embolization-forming composition containing ethyl lactate and method of using the same | |
| JP4817088B2 (en) | Embolization material | |
| CN1270780C (en) | Embolism material | |
| Yang et al. | Injectable PEG/polyester thermogel: A new liquid embolization agent for temporary vascular interventional therapy | |
| US20030223955A1 (en) | Methods for embolizing aneurysmal sites with a high viscosity embolizing composition | |
| US20190231924A1 (en) | Developable Hyaluronic Acid Microspherical Embolic Agent, Preparation Method and Use Thereof | |
| KR102358040B1 (en) | Facilitable Marker Compositions | |
| JP2807075B2 (en) | 5-Hydroxyacetamide-2,4,6-triiodo-isophthalic acid- (2,3-dihydroxy-N-methyl-propyl)-(2-hydroxy-ethyl) -diamide, a process for producing the same, and an X-ray containing the same Contrast agent | |
| WO2001024775A9 (en) | Gel-forming compositions | |
| EP1601392B1 (en) | Compositions for use in embolizing blood vessels comprising high levels of contrast agent | |
| EP3542827A1 (en) | Emulsion composition for chemoembolization and method for producing same | |
| CN117715661A (en) | Pridinosa for NIRF imaging | |
| JP3714972B2 (en) | Hemostasis for injection of diseased tissue abnormal blood vessels | |
| EP4061438A1 (en) | Liquid embolic material composition | |
| AU782654B2 (en) | Embolizing materials | |
| KR100865009B1 (en) | Embolizing materials | |
| JP7442793B2 (en) | Embolic composition, method for producing embolic composition, and embolic kit | |
| Vermess et al. | Infra-Arterial Hepatography: Experimental Evaluation of a New Contrast Agent | |
| TWI299270B (en) | ||
| RU2792585C1 (en) | Composition for blood vessel embolization | |
| CA3225248A1 (en) | Compositions for embolization | |
| CN117982713A (en) | Intravascular embolic composition, and preparation method and application thereof | |
| CZ291597A3 (en) | X-ray contrast agents for computer tomography and urography |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060823 Termination date: 20150409 |
|
| EXPY | Termination of patent right or utility model |